E-DRUG: WHO publishes updated hepatitis C patent reports
--------------------------------------------------------------------------
Knowledge of the patent status of new medicines is important for governments who are trying to make those medicines available to their populations.
To that end, WHO has carried out an analysis of the patent situation for seven of the new treatments, including sofosbuvir, ledipasvir and daclatasvir, all of which have been included in the WHO List of Essential Medicines in 2015. The updated reports provide clarity on whether the medicines are patent protected or not in individual countries.
The dataset was completed for more than 40 countries, territories and regions.
Download the reports here:
http://www.who.int/phi/implementation/ip_trade/ip_patent_landscapes/en/
"BEYER, Peter" <beyerp@who.int>